VECT - VectivBio in licensing deal worth up to $200M for GLP-2 analog apraglutide

VectivBio (NASDAQ:VECT -1.0%) has signed a license agreement with Asahi Kasei Pharma for several indications for the next-generation GLP-2 analog candidate apraglutide. The indications include short bowel syndrome with intestinal failure (SBS-IF) and steroid-refractory acute graft-versus-host disease (aGVHD). Apraglutide is in phase 3 for SBS-IF and phase 1 for aGVHD. Under terms of the deal, VectivBio (VECT -1.0%) will receive a $30M upfront payment, and up to $170M in milestone patments. The company is also eligible for tiered, double-digit royalties on sales of apraglutide in Japan. VectivBio (VECT -1.0%) also entered into a loan facility with Kreos Capital to access up to $75M. Out of three Wall Street analysts covering VectivBio, two rate the company strong buy and one buy.

For further details see:

VectivBio in licensing deal worth up to $200M for GLP-2 analog apraglutide